The treatment paradigm for dry AMD has fundamentally shifted with the introduction of complement pathway inhibitors, marking the first successful pharmacological intervention against Geographic Atrophy (GA), the late-stage, vision-threatening form of the disease. The regulatory approval of drugs like Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) has been hailed as a major breakthrough, directly targeting the immune system’s complement cascade, which is implicated in the inflammation and destruction of retinal cells. This milestone has unlocked a previously untapped segment of the Dry Age Related Macular Degeneration Amd Market, offering hope to millions whose only previous option was disease management through vitamins. While these treatments are administered via invasive intravitreal injection, their ability to slow the rate of GA lesion growth by 14-20% in clinical trials represents a substantial clinical benefit. The commercial success of these early entrants is a powerful indicator of the substantial revenue potential that lies in effective, disease-modifying dry AMD therapies.

However, the current treatment landscape is not without challenges, including the risk of transition to wet AMD and the burden of frequent eye injections. This has spurred intense research into alternative delivery methods and mechanisms of action. The next wave of innovation is focusing on long-acting formulations, or even non-invasive approaches, such as oral drugs and gene therapies that can provide sustained therapeutic benefit and dramatically improve patient adherence.